Evidence map›Paper›PMID 25277147›Full record

ArticleJournal of biomedical optics2014

Spectral-spatial classification for noninvasive cancer detection using hyperspectral imaging.

Guolan Lu, Luma Halig, Dongsheng Wang, Xulei Qin, Zhuo Georgia Chen, Baowei Fei

Abstract read
In one paragraph

Article in Journal of biomedical optics, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 49 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
49citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

49 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Article
  11. Review
  12. Article
  13. Pixel-level Tumor Margin Assessment of Surgical Specimen with Hyperspectral Imaging and Deep Learning Classification.Proceedings of SPIE--the International Society for Optical Engineering · 2021
    Article
  14. Article
  15. Article
  16. Article
  17. Review
  18. Article
  19. Proceedings of SPIE--the International Society for Optical Engineering · 2020
    Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Guolan LuGeorgia Institute of Technology and Emory University, The Wallace H. Coulter Department of Biomedical Engineering, Atlanta, Georgia 30329, United States.
Luma HaligEmory University School of Medicine, Department of Radiology and Imaging Sciences, Atlanta, Georgia 30329, United States.
Dongsheng WangEmory University School of Medicine, Department of Hematology and Medical Oncology, Atlanta, Georgia 30329, United States.
Xulei QinEmory University School of Medicine, Department of Radiology and Imaging Sciences, Atlanta, Georgia 30329, United States.
Zhuo Georgia ChenEmory University School of Medicine, Department of Hematology and Medical Oncology, Atlanta, Georgia 30329, United States.
Baowei FeiGeorgia Institute of Technology and Emory University, The Wallace H. Coulter Department of Biomedical Engineering, Atlanta, Georgia 30329, United StatesbEmory University School of Medicine, Department of Radiology and Imaging Sciences, Atlanta, Georgia 30.

Funding

TARGETING DEATH RECEPTOR-MEDIATED APOPTOSIS FOR HEAD AND NECK CANCERP50CA128613 · NCI · EMORY UNIVERSITY · PI SHIN, DONG M · 2007 to 2011
$12.0M
uPAR Targeted in Vivo Molecular Magnetic Resonance Imaging of....P50CA128301 · NCI · EMORY UNIVERSITY · PI NYE, JONATHON A · 2008 to 2012
$6.8M
MOLECULAR IMAGING DIRECTED, 3D ULTRASOUND-GUIDED, BIOPSY SYSTEMR01CA156775 · NCI · UNIVERSITY OF TEXAS DALLAS · PI FEI, BAOWEI · 2011 to 2016
$1.7M
Targeted fusion biopsy using anti-[18F]FACBC PET/CT and real-time 3D ultrasound gR21CA176684 · NCI · EMORY UNIVERSITY · PI FEI, BAOWEI, MASTER, VIRAJ · 2013 to 2014
$568k
NCI NIH HHS P50 CA128301NCI NIH HHS P50CA128301NCI NIH HHS P50 CA128613NCI NIH HHS P50CA128613NCI NIH HHS R01 CA156775NCI NIH HHS R01CA156775NCI NIH HHS R21 CA176684NCI NIH HHS R21CA176684
6 · The paper itself

Abstract

Early detection of malignant lesions could improve both survival and quality of life of cancer patients. Hyperspectral imaging (HSI) has emerged as a powerful tool for noninvasive cancer detection and diagnosis, with the advantage of avoiding tissue biopsy and providing diagnostic signatures without the need of a contrast agent in real time. We developed a spectral-spatial classification method to distinguish cancer from normal tissue on hyperspectral images. We acquire hyperspectral reflectance images from 450 to 900 nm with a 2-nm increment from tumor-bearing mice. In our animal experiments, the HSI and classification method achieved a sensitivity of 93.7% and a specificity of 91.3%. The preliminary study demonstrated that HSI has the potential to be applied in vivo for noninvasive detection of tumors.

Indexed as

AnimalsCell Line, TumorEarly Detection of CancerMiceNeoplasmsOptical ImagingReproducibility of ResultsSensitivity and SpecificitySpectrum Analysis

Identifiers

PMID25277147
PMCPMC4183763

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.